<![CDATA[Genmab — Juli 2017]]>God morgen. :-). Og god weekend. 😉

]]>https://dev.proinvestor.com/forum/topic/451508/genmab-juli-2017RSS for NodeSun, 14 Jun 2026 07:04:08 GMTSat, 01 Jul 2017 03:06:43 GMT60<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 20:02:01 GMT]]>er blitt spurt tidligere men hvilken tid kommer kvartalsrapporten 9 aug?

]]>https://dev.proinvestor.com/forum/post/10154104https://dev.proinvestor.com/forum/post/10154104Mon, 31 Jul 2017 20:02:01 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 14:46:05 GMT]]>Med

]]>https://dev.proinvestor.com/forum/post/10154105https://dev.proinvestor.com/forum/post/10154105Mon, 31 Jul 2017 14:46:05 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 14:44:53 GMT]]>Måske Lisa som konsulent i indkørselsfasen 😉

]]>https://dev.proinvestor.com/forum/post/10154109https://dev.proinvestor.com/forum/post/10154109Mon, 31 Jul 2017 14:44:53 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 13:22:38 GMT]]>Mcjean - skal du over knæet - fy skam dig.

]]>https://dev.proinvestor.com/forum/post/10154103https://dev.proinvestor.com/forum/post/10154103Mon, 31 Jul 2017 13:22:38 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 13:18:40 GMT]]>Ja Mcjean. Mon ikke pølsemanden havde råd til at modernisere pølsevognen hvis han havde den omsætning. 😄

]]>https://dev.proinvestor.com/forum/post/10154107https://dev.proinvestor.com/forum/post/10154107Mon, 31 Jul 2017 13:18:40 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 13:08:15 GMT]]>11 mia$ eller?, altså omkring 18% af 70 mia, ca. 13 mia kr. ved markedsandel på ca. 25%, lavt sat hvis sc og vedligeholdelse medregnes og udløb af to patenter. For 13 mia kr. om året kan der nok købes en del, måske en ny fabrik måske:-)

]]>https://dev.proinvestor.com/forum/post/10154100https://dev.proinvestor.com/forum/post/10154100Mon, 31 Jul 2017 13:08:15 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 12:33:35 GMT]]>Mht snakken ca kl 10.00 - Novod forventer Dara passerer 5,3 mia i salg 2021 alene i MM. CITI at knap 6 mia passeres i 2021 også i MM. CITI siger totalmarked i 2025 for US (MM) alene vil være 28 mia $ og at verdensmarkedet umiddelbart (normalt) bliver det dobbelte!! (46 mia). Så kan man jo tænke lidt på markedsandel for DARA. CITI regner med 11 mia i topsalg for Dara, men der er mange faktorer

]]>https://dev.proinvestor.com/forum/post/10154102https://dev.proinvestor.com/forum/post/10154102Mon, 31 Jul 2017 12:33:35 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 10:58:25 GMT]]>Thank you E L

]]>https://dev.proinvestor.com/forum/post/10154108https://dev.proinvestor.com/forum/post/10154108Mon, 31 Jul 2017 10:58:25 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 10:54:50 GMT]]>Since you mentioned durvalumab, had news today: IMFINZI™ (durvalumab) granted Breakthrough Therapy Designation by US FDA for patients with locally advanced unresectable non-small cell lung cancer https://www.astrazeneca-us.com/media/press-releases/2017/imfinzi-durvalumab-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer-07312017.html

]]>https://dev.proinvestor.com/forum/post/10154106https://dev.proinvestor.com/forum/post/10154106Mon, 31 Jul 2017 10:54:50 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 10:47:02 GMT]]>H1 2018: Darzalex ph Ib/II data in solid tumours with Roche's
checkpoint inhibitor Tecentriq
H2 2018: Darzalex ph Ib/II data in solid tumours with BMS's
checkpoint inhibitor Opdivo.
Kilde: Nordea

]]>https://dev.proinvestor.com/forum/post/10154096https://dev.proinvestor.com/forum/post/10154096Mon, 31 Jul 2017 10:47:02 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 10:46:55 GMT]]>God eftermiddag. Der er nok at glæde sig til i den kommende tid: Q3-2017: Darzalex ph III ALCYONE frontline MM data with Velcade
H2 2017: ESMO Congress – 8-12 September
H2 2017: Ph II data for Tisotumab Vedotin (likely at ESMO)
H2 2017: Darzalex Ph II data in high-risk smouldering myeloma
(CENTAURUS study) likely in Q4 (ASH)
H2 2017: Darzalex ph II data in multiple myeloma with Celgene’s
durvalumab
H1 2018: Darzalex ph III MAIA frontline MM data with Revlimid

]]>https://dev.proinvestor.com/forum/post/10154098https://dev.proinvestor.com/forum/post/10154098Mon, 31 Jul 2017 10:46:55 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 08:30:51 GMT]]>

favicon

(www.bloodjournal.org)

]]>https://dev.proinvestor.com/forum/post/10154099https://dev.proinvestor.com/forum/post/10154099Mon, 31 Jul 2017 08:30:51 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 08:16:24 GMT]]>OK 🙂

]]>https://dev.proinvestor.com/forum/post/10154097https://dev.proinvestor.com/forum/post/10154097Mon, 31 Jul 2017 08:16:24 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 08:11:49 GMT]]>Sommerferie...

]]>https://dev.proinvestor.com/forum/post/10154093https://dev.proinvestor.com/forum/post/10154093Mon, 31 Jul 2017 08:11:49 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 08:03:33 GMT]]>Der er an meget afventende handel med Genmap. Er det mon udtryk for en afventen med hensyn til halvårsregnskabet den 9. Aug?

]]>https://dev.proinvestor.com/forum/post/10154090https://dev.proinvestor.com/forum/post/10154090Mon, 31 Jul 2017 08:03:33 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 07:28:28 GMT]]>Men der er mange bud.....http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi

]]>https://dev.proinvestor.com/forum/post/10154091https://dev.proinvestor.com/forum/post/10154091Mon, 31 Jul 2017 07:28:28 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 07:27:00 GMT]]>
Just a moment...

favicon

(www.grandviewresearch.com)

]]>https://dev.proinvestor.com/forum/post/10154094https://dev.proinvestor.com/forum/post/10154094Mon, 31 Jul 2017 07:27:00 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 07:26:42 GMT]]>The global multiple myeloma therapeutics market was valued at USD 7.5 billion in 2015 and is expected to reach a value of USD 37.5 billion by 2024. Key factors driving the market expansion include constant introduction of newer and effective therapeutic options and high adoption rates of the same.

]]>https://dev.proinvestor.com/forum/post/10154092https://dev.proinvestor.com/forum/post/10154092Mon, 31 Jul 2017 07:26:42 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 06:32:44 GMT]]>Beklager min fejl information. Det Michael Novod har informeret at M.M markedet vil være ca. 9B USD i 2020 og det er sikkert revideret efter denne artikel fra 2013 http://www.firstwordpharma.com/node/1066623?tsid=21#axzz4oOXUDX45

]]>https://dev.proinvestor.com/forum/post/10154089https://dev.proinvestor.com/forum/post/10154089Mon, 31 Jul 2017 06:32:44 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 06:24:46 GMT]]>hov - blev lige afbrud - jo 2025-2027 stykker

]]>https://dev.proinvestor.com/forum/post/10154088https://dev.proinvestor.com/forum/post/10154088Mon, 31 Jul 2017 06:24:46 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 06:23:58 GMT]]>Jo peaksale på 9B USD men ikke i 2020

]]>https://dev.proinvestor.com/forum/post/10154101https://dev.proinvestor.com/forum/post/10154101Mon, 31 Jul 2017 06:23:58 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 06:22:41 GMT]]>lyder vildt! er det ikke omkring 2025 så?

]]>https://dev.proinvestor.com/forum/post/10154083https://dev.proinvestor.com/forum/post/10154083Mon, 31 Jul 2017 06:22:41 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 06:17:29 GMT]]>Nej det er M.M marked på 9B USD som han tidligere har nævnt

]]>https://dev.proinvestor.com/forum/post/10154084https://dev.proinvestor.com/forum/post/10154084Mon, 31 Jul 2017 06:17:29 GMT<![CDATA[Reply to Genmab — Juli 2017 on Mon, 31 Jul 2017 06:14:18 GMT]]>Novod har da ikke 9B USD i 2020 - mon ikke det ligger på 4-5B USD forudsat at 1. linie går igennem

]]>https://dev.proinvestor.com/forum/post/10154086https://dev.proinvestor.com/forum/post/10154086Mon, 31 Jul 2017 06:14:18 GMT